



GlaxoSmithKline Consumer Healthcare Ltd.

24-25 Floor, One Horizon Center
Sector 43, DLF Phase 5, Golf Course Road
Gurugram (Haryana), India - 122002

T +91 124 4336500
F +91 124 4336600
E contact.4.gsk@gsk.com
www.gsk.com

June 26, 2018

The Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, C – 1, Block – G
Bandra-Kurla Complex, Bandra
Mumbai – 400 051

Dear Sir/Madam,

Dear Sir/Madam,

Sub: Clarification/Confirmation on news item appearing in "www.economictimes.indiatimes.com/"

In response to your letter no. NSE/CM/Surveillance/ 7528 dated June 26, 2018, we would like to inform you that the Company had made necessary disclosures on March 27, 2018 attached herewith as Annexure "A" noting the announcement by GlaxoSmithKline plc (GSK) of its intent to carry out a strategic review of GSK's Horlicks and its other consumer nutrition products which will include an assessment of its 72.45% shareholding in the Company.

The Company is not aware of any negotiations as referred to in the news article.
Thanking You

Yours faithfully
For GlaxoSmithKline
Consumer Healthcare Limited

Shanu Saksena
Company Secretary
M. No. ACS-13405

ANNEXURE - A



GlaxoSmithKline Consumer Healthcare Ltd.
24-25 Floor, One Horizon Center
Sector 43, DLF Phase 5, Golf Course Road
Gurugram (Haryana), India - 122002

T +91 124 4336500
F +91 124 4336600
E contact.4.gsk@gsk.com
www.gsk.com

March 27, 2018

The Corporate Relationship Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400001

The Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block - G
Bandra-Kurla Complex, Bandra
Mumbai - 400 051

Dear Sir/Madam,

Sub: Strategic Review of Horlicks and Other Consumer Nutrition Products

This is to notify that the Company notes the announcement by GlaxoSmithKline plc (GSK) of its intent to carry out a strategic review of GSK's Horlicks and its other consumer nutrition products which will include an assessment of its 72.45% shareholding in the Company.

The above may please be taken as our intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking You

Yours faithfully
For GlaxoSmithKline
Consumer Healthcare Limited

A handwritten signature in blue ink, appearing to read 'Shanu'.

Shanu Saksena
Company Secretary
M. No. ACS-13405